Skip to main contentAI and Advanced
/
AJANTPHARM · NSEBSE SENSEX77,537.72+0.82%BSE |
NIFTY 5024,231.85+0.64%NSE |
NIFTY BANK57,495.9+0.45%NSE |
NIFTY IT30,673.05+0.79%NSE |
NIFTY AUTO29,301.75+0.40%NSE |
NIFTY FMCG47,863.25+0.82%NSE |
NIFTY PHARMA26,416+0.39%NSE |
NIFTY 50023,512.95+0.54%NSE |
AJ
NSE · Equity shares · Biotechnology & Drugs0.00 · 0.00%
Ajanta Pharma AJANTPHARM
NSE:INR 3,690
BSE:INR 3,446.95
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for AJANTPHARM
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 3,690
Day rangeINR 3,615 — INR 3,789
52-week rangeINR 2,329.9 — INR 3,796
Volume69,375
Market cap43,108.56
P/E37.68
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)5,452.86
Net Income (INR Cr)1,056
Rev Growth (5 Year %)13.54
EPS Growth (5 Year %)11.04
P/E Ratio37.68
EPS84.63
Research path: Interpret Ajanta Pharma's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
AJANTPHARMAjanta Pharma1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 6,154.84 | 5,014.95 | 4,638.39 |
| Accumulated Depreciation Total | -1,129.33 | -1,002.48 | -881.04 |
| Other Liabilities Total | 54.64 | 83.32 | 43.76 |
| Common Stock Total | 25.07 | 25.07 | 25.27 |
| Other Equity Total | 41.37 | 12.29 | 10.44 |
| Other Current Assets Total | 1.2 | 14.45 | 22.61 |
| Prepaid Expenses | 32.55 | 24.58 | 25.92 |
| Total Assets | 6,154.84 | 5,014.95 | 4,638.39 |
| Current Portof LT Debt/Capital Leases | 13.86 | 12.7 | 11.76 |
| Additional Paid-In Capital | 7.16 | 3.66 | 0.18 |
| Cash | 103.26 | 175.12 | 129.49 |
| Total Equity | 4,527.09 | 3,790.29 | 3,567.36 |
| Long Term Investments | 28.5 | 25.24 | 18.58 |
| Retained Earnings(Accumulated Deficit) | 4,450.27 | 3,744.09 | 3,525.82 |
| Total Common Shares Outstanding | 12.49 | 12.49 | 12.59 |
| Property/Plant/Equipment Total-Gross | 3,212.75 | 2,894.25 | 2,602.02 |
| Tangible Book Valueper Share Common Eq | 359.03 | 299.71 | 282.15 |
| Total Liabilities | 1,627.75 | 1,224.66 | 1,071.03 |
| Total Debt | 260.17 | 47.42 | 35.28 |
| Short Term Investments | 560.16 | 438.71 | 330.05 |
| Cashand Short Term Investments | 663.42 | 613.83 | 459.54 |
| Total Receivables Net | 2,030.38 | 1,247.05 | 1,356.25 |
| Notes Payable/Short Term Debt | 206.89 | 0 | 0 |
| Deferred Income Tax | 117.94 | 110.52 | 108.5 |
| Accounts Receivable-Trade Net | 1,862.4 | 1,185.03 | 1,253.38 |
| Property/Plant/Equipment Total-Net | 2,083.42 | 1,891.77 | 1,720.98 |
| Total Current Liabilities | 1,415.75 | 996.1 | 895.25 |
| Total Inventory | 1,007.88 | 943.12 | 866.6 |
| ESOP Debt Guarantee | 3.22 | 5.18 | 5.65 |
| Accounts Payable | 544.3 | 454.2 | 463.2 |
| Other Currentliabilities Total | 650.7 | 529.2 | 420.29 |
| Total Long Term Debt | 39.42 | 34.72 | 23.52 |
| Intangibles Net | 41.58 | 46.52 | 14.66 |
| Other Long Term Assets Total | 195.25 | 195.65 | 143.79 |
| Note Receivable-Long Term | 70.66 | 12.74 | 9.46 |
| Total Current Assets | 3,735.43 | 2,843.03 | 2,730.92 |
| Capital Lease Obligations | 39.42 | 34.72 | 23.52 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.68
Price to Sale Ratio7.91
Growth
Debt 5Yr CAGR %52.68
Margins
Operating Margin 12m23.58
Operating Margin 5y Avg23.35
Net Profit Margin 12m19.65
Net Profit Margin 5y19.13
Yield
Dividend Yield %0.81
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk28.51
Analyst consensus
ConsensusBuy
Consensus score2.07
Analyst opinions15
Strong Sell count0
Sell count2
Hold count3
Buy count4
Strong Buy count6
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 63.48%
- FII
- 7.68%
- MF
- 18.10%
- Other
- 10.74%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Top 14 Pharma Stocks To Buy In India July 2026 - SamcoMarket news · 21 Jul 2026, 12:21 pm
Top 14 Pharma Stocks To Buy In India July 2026 Samco
Ajanta Pharma approves financial statements at AGM - scanx.tradeMarket news · 18 Jul 2026, 12:57 am
Ajanta Pharma approves financial statements at AGM scanx.trade
Ravi Agrawal releases pledge on 2,600 Ajanta Pharma shares - scanx.tradeMarket news · 14 Jul 2026, 10:50 am
Ravi Agrawal releases pledge on 2,600 Ajanta Pharma shares scanx.trade
Ajanta Pharma Ltd gains for third consecutive session - Business StandardMarket news · 13 Jul 2026, 1:17 pm
Ajanta Pharma Ltd gains for third consecutive session Business Standard
Five Trends That Will Shape the Future of Obesity Care in India: Ajanta Pharma Shares Its Perspective on the Next Decade of Metabolic Health - TheWire.inMarket news · 9 Jul 2026, 4:09 pm
Five Trends That Will Shape the Future of Obesity Care in India: Ajanta Pharma Shares Its Perspective on the Next Decade of Metabolic Health TheWire.in
Ajanta Pharma has received the Establishment Inspection Repo - KuCoinMarket news · 8 Jul 2026, 7:39 pm
Ajanta Pharma has received the Establishment Inspection Repo KuCoin
Corporate actions
Events
- dividendRs.32.0000 per share(1600%)First Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- annual General MeetingAGM
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- dividendRs.28.0000 per share(1400%)First Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board MeetingsTo consider other business matters.
ShareKeyX Community
Discussion and sentiment for Ajanta Pharma
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- AJANTPHARM
- BSE Code
- 532331
Questions
Stock FAQ
What is the symbol and ISIN of Ajanta Pharma?
Ajanta Pharma has the symbol AJANTPHARM and ISIN - INE031B01049.
What is the current price of Ajanta Pharma?
Ajanta Pharma is currently trading at INR 3,690.00.
What are the year high and year low of Ajanta Pharma?
Ajanta Pharma has a year high of INR 3,796.00 and a year low of INR 2,329.90.
What is the market capitalization of Ajanta Pharma?
Ajanta Pharma has a market capitalization of INR 43,108.56 crore.
What is the P/E ratio of Ajanta Pharma?
Ajanta Pharma has a P/E ratio of 37.68.
What is the dividend yield of Ajanta Pharma?
Ajanta Pharma has a dividend yield of 0.81%.
How is the financial performance of Ajanta Pharma based on revenue, net income, and EPS?
Ajanta Pharma has revenue of INR 5,452.86 crore, net income of INR 1,056.00 crore, and EPS of INR 90.83.
What is the book value of Ajanta Pharma?
Ajanta Pharma has a book value of NA.
What is the debt-to-equity ratio of Ajanta Pharma?
Ajanta Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Ajanta Pharma?
Ajanta Pharma has a price-to-book ratio of NA and a price-to-sales ratio of 7.91.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.